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Recombinant  viral  vectors  provide  an effective  means  for  heterologous  antigen  expression  in vivo and
thus  represent  promising  platforms  for developing  novel  vaccines  against  human  pathogens  from  Ebola
to  tuberculosis.  An  increasing  number  of candidate  viral  vector  vaccines  are  entering  human  clinicalvailable online 8 October 2014
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trials.  The  Brighton  Collaboration  Viral  Vector  Vaccines  Safety  Working  Group (V3SWG)  was  formed  to
improve  our  ability  to anticipate  potential  safety  issues  and  meaningfully  assess  or interpret  safety  data,
thereby  facilitating  greater  public  acceptance  when  licensed.
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mmunization
The Brighton Collaboration was launched in 2000 to improve the
cience of vaccine safety [1] – an issue that had become increasingly
ontroversial and prominent worldwide, particularly in countries
ith mature immunization programs which had nearly elimi-
ated targeted vaccine-preventable diseases [2–4]. To provide a
 The ﬁndings, opinions, conclusions, and assertions contained in this consensus
ocument  are those of the individual members of the Working Group. They do not
ecessarily represent the ofﬁcial positions of each participant’s organization (e.g.,
overnment, university, or corporations) and should not be construed to represent
ny  Agency determination or policy.
∗ Corresponding author. Tel.: +1 404 639 3755; fax: +1 404 639 6217.
E-mail addresses: brightoncollaborationv3swg@gmail.com, bchen@cdc.gov
R.T. Chen).
1 Retired.
2 See Acknowledgment for other V3SWG members.
ttp://dx.doi.org/10.1016/j.vaccine.2014.09.035
264-410X/Published by Elsevier Ltd. Open access under CC BY-NC-ND license.common vocabulary for vaccine safety researchers, the Brighton
Collaboration focused its initial efforts on developing standardized
case deﬁnitions for adverse events following immunizations (AEFI),
including guidelines for data collection, analysis, and presentation
[5]. To date, over 30 AEFI case deﬁnitions have been developed
by voluntary Brighton working groups, endorsed by normative
bodies such as the Council of International Organizations of Med-
ical Science (CIOMS) [6], the U.S., Food and Drug Administration
(FDA) [7], and the European Medicines Agency (EMA) [8] and are
freely available for public use at www.brightoncollaboration.org.
These  Brighton AEFI case deﬁnitions are increasingly being used
and recognized as “common currency”, allowing greater ease in
comparing vaccine safety studies. This was  evidenced in recent
international studies of intussusception after rotavirus vaccina-
tion [9], Guillain–Barre/Fisher syndrome [10], and narcolepsy after
inﬂuenza vaccination [11].
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Table  1
Issues of critical importance to be investigated by Brighton Collaboration Viral Vector Vaccine Safety Working Group (V3SWG).a
1) Potential of recombination of the viral vector vaccine with wild type pathogenic strains.
a)  Vector–circulating virus could create a more pathogenic strain.
b)  This issue should be addressed in vitro or in animal studies.
2)  Implications of prior infections on the immunogenicity of vectored vaccines.
a) Prior infection with related viruses may  reduce vaccine immunogenicity (e.g., adenoviruses, poxviruses (smallpox vaccine))
b)  Immunogenicity of subsequent doses, especially with different gene in same vector (e.g., modiﬁed poxviruses, adenoviruses): should be addressed if relevant.
3) Genetic stability of replicating recombinant viruses in vivo should be studied focusing on:
a) The sequence insert, and known areas of attenuation
b)  Known epitopes
4)  The impact of the addition of foreign genes on the pathogenicity of the viral vaccine vector when compared to the parent virus.b
5) Tests for absence of reversion to virulence should be performed when an attenuated vector is used.
6)  The absence of replication competent virus when replication incompetent vectors are used should be demonstrated.
7) Public acceptance of vectored vaccines with speciﬁc safety concerns could be an issue. A need for a forum to discuss concerns, and how best to communicate the
risks and beneﬁts of the new approach to general public was identiﬁed and WHO  was  requested to take a lead on it.
8) Assessing vectored vaccine effects on innate immunity and on the possible induction of an immuno- suppressive window or alternatively immune activation.
9)  Deﬁning the length of time for monitoring AEFIs after receipt of vectored vaccines.
10) Developing guidelines for archiving samples of vectored vaccine samples to enable potential future testing to assess inadvertent contamination by adventitious
agents.
11) Assessing possible secondary transmission of vectored vaccine virus.
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b originally: Potential changes of tropism may  lead to know properties of replica
talicized = modiﬁcations/updates by the V3SWG.
While vaccine safety issues are frequently most prominent in
he post-licensure setting when administered to larger and hetero-
eneous populations, they should be viewed as a continuum with
 product life cycle that begins pre-licensure [12–14]. Consistent
ith this, each Brighton Collaboration case deﬁnition is designed
or use in pre- and post-licensure setting, and are associated with
uidelines for collection, analysis and presentation of vaccine safety
ata in pre- and post-licensure clinical studies [15], including a
emplate protocol [16].
Since  traditional methods of vaccine development have failed
or several major human pathogens (e.g., human immunodeﬁ-
iency virus (HIV), tuberculosis, and malaria), new approaches
merging from the biotechnology revolution are being explored
17]. Amongst these new approaches, recombinant viral vectors
rovide an efﬁcient means for heterologous antigen expression
n vivo and thus provide a promising platform for developing novel
accines against diseases that have posed a challenge to vaccine
evelopment [18–26]. Some veterinary viral vector vaccines have
een licensed [24] but there is as yet limited clinical experience of
he efﬁcacy and safety of such vectors in humans. A 2003 World
ealth Organization (WHO) informal consultation on the charac-
erization and quality aspects of vaccines based on live viral vectors
27] and the EMA’s guideline on quality, non-clinical and clinical
spects of live recombinant viral vectored vaccines [28] identiﬁed
everal issues of critical importance which warrant further inves-
igation. These include recombination with wild-type pathogenic
trains and exploration of public acceptance (see items 1–7 in
able 1).
With  increasing numbers of viral vectors now entering human
linical trials, there is an urgent need to establish appropriate reg-
latory measures to ensure their quality, safety and efﬁcacy. This
eed was highlighted by recent developments such as:
1)  planned expedited human trials of two Ebola vaccine candi-
dates;  one using chimp adenovirus 3 (ChAd3) and the other
recombinant vesicular stomatitis virus (rVSV) viral vector[29],
2) the higher rates of HIV acquisition among participants of the
STEP  [30,31] and Phambili [32] trials who had received a
replication-defective Ad5 vector vaccine candidate,3) the ﬁrst HIV vaccine candidate to show (modest) protection
in  large human trials consisted of a recombinant canary pox
virus  vector vaccine (ALVAC-HIV [vCP1521]) and a recombinant
glycoprotein 120 subunit vaccine [33], andpect of vaccines based on live viral vectors, December 2003 [27]; items 8–11 added
ruses and should be carefully evaluated.
(4) the development of a recombinant rhesus cytomegalovirus
(CMV) vaccine vector engineered to express simian immu-
nodeﬁciency virus (SIV) proteins that resulted in progressive
clearance of a pathogenic SIV infection in rhesus macaques [34].
Speciﬁc to the Brighton Collaboration, improving our ability
to anticipate safety issues and meaningfully assess and interpret
safety data from trials of new viral vector vaccines will enhance
public conﬁdence for their safety and efﬁcacy. With encouragement
of the WHO’s Initiative for Vaccine Research, the Brighton Collab-
oration formed the Viral Vector Vaccines Safety Working Group
(V3SWG) in October 2008 to help standardize the collection, anal-
ysis and dissemination of safety data regarding viral vector vaccines
in pre- and post-licensure settings. As with other Brighton Collab-
oration working groups, the V3SWG was formed by identifying a
critical mass (N ∼ 15 from initial >300 interested individuals) of aca-
demic, government, and industry volunteers with the appropriate
expertise and interest in vaccine safety and virology. Through email
exchanges and monthly conference calls coordinated by a secre-
tariat at the CDC Division of HIV/AIDS Prevention, the V3SWG has
focused on two  main sets of activities.
First, the V3SWG adopted the list of seven issues of critical
importance needing further investigation as identiﬁed by the 2003
WHO  consultation on live viral vectors (see the ﬁrst seven issues
listed in Table 1) and added four additional issues (see last four
issues listed in Table 1).
By  addressing several issues simultaneously, the V3SWG hopes
to develop harmonized guidelines which will enhance comparabil-
ity and interpretation of data.
Second, recognizing the value of Brighton Collaboration stan-
dardized case deﬁnitions for AEFI, the V3SWG is working to develop
a standardized template describing the key characteristics of a
novel vaccine vector to facilitate the scientiﬁc discourse among
key stakeholders and increase the transparency and comparability
of information. Fortuitously, the International AIDS Vaccine Initia-
tive (IAVI) had developed an internal template tool to assess the
risk/beneﬁt of different viral vectors. This tool aimed at ﬂagging
issues that may  either be showstoppers or need to be carefully
addressed, helping to prioritize vector development activities.
The template gathers information on the characteristics of the
wild type virus from which the vector was  derived; it also aids
in the ascertainment of known effects of the proposed vaccine
vector in animals and humans, manufacturing details, toxicology
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nd potency, pre-clinical studies, and human use with an over-
ll adverse effect and risk assessment. The IAVI kindly shared this
ool with the V3SWG for adaptation and broader use as a stan-
ardized template for collection of key information for risk/beneﬁt
ssessment on any viral vector vaccines.
In this issue of Vaccine, Monath et al. publishes the ﬁrst com-
leted Brighton Collaboration V3SWG template on Risk/Beneﬁt
ssessment for Live Virus Vaccines Based on a Yellow Fever Vaccine
ackbone [35]. The V3SWG hopes that eventually, all develop-
rs/researchers of viral vector vaccines, especially those likely to be
sed in humans, will complete this template and submit it to the
3SWG and Brighton Collaboration for peer review, and eventual
ublication in Vaccine. We  recognize that while desirable, the infor-
ation needed to complete the entire template, especially from
eer reviewed scientiﬁc publications or systematic reviews, may
urrently be unavailable for a new candidate vector vaccine. Nev-
rtheless, the existence of such gaps in current knowledge should
ot deter researchers from initiating completion of the template
o the best of their ability; any gaps may  provide a constructive
ignal for prioritizing areas of future research. We  also recognize
hat some researchers and sponsors may  wish to delay sharing
ome information for proprietary or intellectual property reasons.
opefully, such a stance will evolve as the development of a viral
ector vaccine candidate “matures” from evaluation in human tri-
ls and the need for information sharing and transparency grows
o maximize public acceptance. Furthermore, it is likely that the
ace of accumulation of new scientiﬁc knowledge during vaccine
evelopment may  be more rapid than changes in clinical diagnosis
elevant to AEFI case deﬁnitions. Therefore, the Brighton Collabora-
ion V3SWG hopes to maintain these templates in a dynamic “wiki”
tyle (i.e., online collaborative editing) with the help of each vector
accine research “community.” We  seek your assistance to identify
nd encourage researchers of new viral vector vaccine candidates
o complete a template and join in the subsequent vector-speciﬁc
iki community in this exciting new era of vaccine development
uring this as well as in future decades [36].
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